Cargando…
Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites
The World Health Organization estimates the number of people suffering from depression to be over 264 million. Current monoamine transmission modulating therapeutics, even with proper adherence and acceptable tolerability, are not effective for nearly one third of the patients, leading clinicians to...
Autores principales: | Makunts, Tigran, Wollmer, Marc Axel, Abagyan, Ruben |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393507/ https://www.ncbi.nlm.nih.gov/pubmed/32732918 http://dx.doi.org/10.1038/s41598-020-69773-7 |
Ejemplares similares
-
Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety
por: Wollmer, M. Axel, et al.
Publicado: (2021) -
Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data
por: Joulfayan, Haroutyun, et al.
Publicado: (2023) -
Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis
por: Makunts, Tigran, et al.
Publicado: (2019) -
Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
por: Cohen, Isaac V., et al.
Publicado: (2017) -
Publisher Correction: Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
por: Cohen, Isaac V., et al.
Publicado: (2017)